Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · December 05, 2019

Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib as First Treatment for Patients With Unresectable Hepatocellular Carcinoma

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
IMbrave150: Efficacy and Safety Results From a ph III Study Evaluating Atezolizumab (Atezo) + Bevacizumab (Bev) vs Sorafenib (Sor) as First Treatment (Tx) for Patients (Pts) With Unresectable Hepatocellular Carcinoma (HCC)
Ann. Oncol 2019 Nov 24;[EPub Ahead of Print], A-L Cheng, S Qin, M Ikeda, P Galle, M Ducreux, A Zhu, T-Y Kim, M Kudo, V Breder, P Merle

Further Reading